Recombinant Human IFNG, Gln24-Gln166, was produced in E. coli using non-animal reagents in an animal-free facility under cGMP guidelines.
Lyophilized from a 0.2 μm filtered solution in Sodium Succinate, Mannitol and Tween® 80.
Measured in anti-viral assays using HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. Meager, A. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 129. The ED50 for this effect is 0.15-0.75 ng/mL.
The specific activity of recombinant human IFN-gamma is approximately 2 x 10^4 IU/μg, which is calibrated against human IFN-gamma Standard (NIBSC code: 87/586).
Predicted Molecular Mass: 16.9 kDa
SDS-PAGE: 17 kDa, reducing conditions
N-terminal Sequence Analysis:
<0.01 EU per 1 μg of the protein by the LAL method.
>97%, by SDS-PAGE with silver staining, under reducing
Avoid repeated freeze-thaw cycles.
12 months, -20 to -70 centigrade as supplied.
1 month, 2 to 8 centigrade under sterile conditions after reconstitution.
3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
Reconstitute at 200 μg/mL in sterile, deionized water.
Our GMP proteins are produced according to relevant sections of the following documents: WHO TRS, No. 822, 1992 Annex 1, Good Manufacturing Practices for Biological Products; USP Chapter 1043, Ancillary Materials for Cell, Gene and Tissue-Engineered Products and USP Chapter 92, Growth Factors and Cytokines Used in Cell Therapy Manufacturing.
The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.